Incorporating option values into the economic evaluation of health care technologies
- PMID: 11184803
- DOI: 10.1016/s0167-6296(00)00048-5
Incorporating option values into the economic evaluation of health care technologies
Abstract
Despite uncertainty being intrinsic to economic evaluation of health care, existing techniques for handling uncertainty remain underdeveloped compared to the formal techniques commonly applied in the business sector. This paper develops an alternative approach to handling uncertainty in economic evaluation based on 'option-pricing' techniques. The presence of uncertainty and the degree of irreversibility of a decision make it clear that some flexibility in the timing of a decision is often a desirable characteristic with an economic value. We demonstrate how option-pricing techniques can be applied to the decision rules for economic evaluation in health care. The key determinants of an option value are the presence and type of uncertainty; the ability to defer a decision; and the irreversibility of the decision. The relative significance of each of these for a particular economic evaluation will depend on the particular characteristics of the technology under consideration.
Similar articles
-
Representing uncertainty: the role of cost-effectiveness acceptability curves.Health Econ. 2001 Dec;10(8):779-87. doi: 10.1002/hec.635. Health Econ. 2001. PMID: 11747057
-
Cost effectiveness/utility analyses. Do current decision rules lead us to where we want to be?J Health Econ. 1992 Oct;11(3):279-96. doi: 10.1016/0167-6296(92)90004-k. J Health Econ. 1992. PMID: 10122540 Review.
-
Optimal decision rules for HTA under uncertainty: a wider, dynamic perspective.Health Econ. 2013 Dec;22(12):1507-14. doi: 10.1002/hec.2893. Epub 2012 Dec 7. Health Econ. 2013. PMID: 23225192
-
The importance of model inputs and assumptions in conducting health technology assessments of novel drugs.J Med Econ. 2017 Oct;20(10):1107-1109. doi: 10.1080/13696998.2017.1359182. Epub 2017 Aug 4. J Med Econ. 2017. PMID: 28737052 No abstract available.
-
Welfare economics and cost-utility analysis.Dev Health Econ Public Policy. 1992;1:143-57. doi: 10.1007/978-94-011-2392-1_7. Dev Health Econ Public Policy. 1992. PMID: 10151743 Review. No abstract available.
Cited by
-
A comprehensive update on the cost-effectiveness of 10-year denosumab vs alendronate in postmenopausal women with osteoporosis in the United States.Arch Osteoporos. 2025 Jun 30;20(1):85. doi: 10.1007/s11657-025-01564-x. Arch Osteoporos. 2025. PMID: 40588656 Free PMC article.
-
Making a decision to wait for more evidence: when the National Institute for Health and Clinical Excellence recommends a technology only in the context of research.J R Soc Med. 2007 Oct;100(10):453-60. doi: 10.1177/014107680710001013. J R Soc Med. 2007. PMID: 17911127 Free PMC article. No abstract available.
-
Role of pharmacoeconomic analysis in R&D decision making: when, where, how?Pharmacoeconomics. 2005;23(1):1-12. doi: 10.2165/00019053-200523010-00001. Pharmacoeconomics. 2005. PMID: 15693724 Review.
-
Should Countries Set an Explicit Health Benefits Package? The Case of the English National Health Service.Value Health. 2017 Jan;20(1):60-66. doi: 10.1016/j.jval.2016.01.004. Value Health. 2017. PMID: 28212971 Free PMC article.
-
A Decision Rule for Determining the Optimal Transplant Listing Window for Patients With a Fontan Physiology.MDM Policy Pract. 2021 Nov 15;6(2):23814683211057472. doi: 10.1177/23814683211057472. eCollection 2021 Jul-Dec. MDM Policy Pract. 2021. PMID: 34805528 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources